

GEORGIA MEDICAID FEE-FOR-SERVICE VASODILATORS, CORONARY PA SUMMARY

| Preferred | Non-Preferred |
|---|---|
| Dilatrate SR (isosorbide dinitrate SR) Isordil (isosorbide dinitrate) Isosorbide dinitrate generic Isosorbide mononitrate generic Isosorbide mononitrate ER generic Minitran (nitroglycerin transdermal patch) Nitro-Bid (nitroglycerin ointment) Nitro-Dur 0.8 mg/hour (nitroglycerin transdermal patch) Nitroglycerin transdermal patch generic Nitroglycerin sublingual tablets generic Nitrostat (nitroglycerin sublingual tablets) | BiDil (isosorbide dinitrate/hydralazine hydrochloride) GoNitro (nitroglycerin sublingual powder) Nitroglycerin lingual spray generic Verquvo (vericiguat) |

SR=sustained release; ER=extended release

LENGTH OF AUTHORIZATION: 1 Year

PA CRITERIA:

<u>BiDil</u>

❖ Prescriber must submit a written letter of medical necessity stating the reasons the preferred products, generic isosorbide dinitrate and generic hydralazine, are not appropriate for the member.

GoNitro and Nitroglycerin Lingual Spray Generic

❖ Prescriber must submit a written letter of medical necessity stating the reasons the preferred products, generic nitroglycerin sublingual tablets and brand Nitrostat sublingual tablets, are not appropriate for the member.

Verquvo

❖ Approvable for members 18 years of age and older with a diagnosis of New York Heart Association (NYHA) Class II-IV or American College of Cardiology/American Heart Association (ACC/AHA) Stage C-D chronic heart failure and left ventricular ejection fraction (LVEF) <45% who have been hospitalized for heart failure within the past 6 months or received an outpatient intravenous (IV) diuretic within the past 3 months

AND

- Member must have experienced an inadequate response, allergies, contraindications, drug-drug interactions or intolerable side effects with at least one medication in at least three of the following classes:
 - □ Sodium-glucose transport protein 2 [SGLT-2] inhibitors (e.g., dapagliflozin [Farxiga], canagliflozin [Invokana], empagliflozin [Jardiance])
 - □ Angiotensin-converting enzyme [ACE] inhibitors (e.g., enalapril, lisinopril), Angiotensin receptor blockers [ARBs] (e.g., losartan, valsartan, candesartan) or



| Angiotensin receptor-neprilysin inhibitor [ARNI] (e.g., sacubitril/valsartan |
|--|
| [Entresto]) |
| Beta blockers (e.g., bisoprolol, carvedilol, metoprolol succinate) |
| Aldosterone antagonists (e.g., spironolactone, eplerenone) |

EXCEPTIONS:

- Exceptions to these conditions of coverage are considered through the prior authorization process.
- The Prior Authorization process may be initiated by calling **OptumRx at 1-866-525-5827.**

PREFERRED DRUG LIST:

• For online access to the Preferred Drug List (PDL), please go to http://dch.georgia.gov/preferred-drug-lists.

PA AND APPEAL PROCESS:

 For online access to the PA process, please go to <u>www.dch.georgia.gov/prior-authorization-process-and-criteria</u> and click on Prior Authorization (PA) Request Process Guide.

QUANTITY LEVEL LIMITATIONS:

 For online access to the current Quantity Level Limits (QLL), please go to <u>www.mmis.georgia.gov/portal</u>, highlight Pharmacy and click on <u>Other Documents</u>, then select the most recent quarters QLL list.